BMS fills hole left by Hooper
This article was originally published in Scrip
Bristol-Myers Squibb has promoted Giovanni Caforio to president of US pharmaceuticals, and Charles Bancroft and Béatrice Cazala have been appointed executive vice-presidents, both replacing Anthony Hooper, previously BMS' senior vice-president of commercial operations and president of the US, Japan/Pacific Rim and Intercontinental businesses. Mr Caforio was most recently senior vice-president of oncology and immunology global commercialisation. Mr Bancroft is currently CFO, and will add his new responsibilities to this role, while Ms Cazala will carry on her duties as the leader of global commercialisation in Europe and the emerging markets.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.